Denali Therapeutics stock falls after Parkinson’s drug fails trial
Denali Therapeutics Inc. shares fell after its experimental Parkinson’s disease treatment, BIIB122 (DNL151), failed to meet primary or secondary endpoints in a late-stage clinical trial. Partner Biogen Inc. also saw a stock drop. Despite showing biological effects in reducing LRRK2 activity, the drug did not translate to clinical benefit in slowing disease progression.
Wedbush Cuts Price Target on Denali Therapeutics to $20 From $23, Keeps Outperform Rating
Wedbush has lowered its price target for Denali Therapeutics (DNLI) to $20 from $23, while maintaining an Outperform rating on the stock. This adjustment comes amidst other analyst revisions and recent news, including the discontinuation of a Parkinson's drug development program by Denali and Biogen. The article also provides a brief company profile of Denali Therapeutics, highlighting its focus on biotherapeutics for neurological diseases.
Denali Therapeutics and Biogen discontinue BIIB122 after Phase 2b LUMA misses endpoints
Denali Therapeutics and Biogen have discontinued their Parkinson's disease drug BIIB122 after its Phase 2b LUMA study failed to meet primary and secondary endpoints in early-stage Parkinson’s disease. Despite showing high LRRK2 kinase inhibition, the drug did not slow disease progression compared to placebo. Denali will continue a separate Phase 2a BEACON study for LRRK2 variant carriers, with data expected in the first half of 2027.
Biogen, Denali discontinue Parkinson’s drug after trial fails
Biogen and Denali Therapeutics have announced the discontinuation of their Parkinson's drug, BIIB122, following the failure of its Phase 2b LUMA study to meet primary and secondary endpoints. The drug, an investigational small molecule inhibitor of LRRK2, did not slow disease progression in early-stage Parkinson’s patients. Despite this setback, Denali will continue a separate Phase 2a study for LRRK2 variant carriers, with results expected in early 2027, while Biogen also faces mixed results and analyst updates on other pipeline drugs.
[8-K] Denali Therapeutics Inc. Reports Material Event
Denali Therapeutics Inc. and Biogen announced that their Phase 2b LUMA study of BIIB122 (DNL151) for early-stage Parkinson’s disease failed to meet its primary and secondary endpoints. Consequently, development of BIIB122 for idiopathic Parkinson's disease will be discontinued. Denali will, however, continue with the separate Phase 2a BEACON study in individuals with Parkinson’s disease who carry a pathogenic LRRK2 variant, with data expected in the first half of 2027.
DNLI gains 25.4% year to date: Should you buy, sell or hold the stock?
The article discusses Denali Therapeutics (DNLI) stock performance, noting a 25.4% year-to-date gain, and asks whether investors should buy, sell, or hold the stock. It provides an overview of the company's financial health, including key performance indicators like market capitalization, P/E ratio, and recent earnings, to help inform investment decisions.
Denali Therapeutics Says AVLAYAH Launch Ahead of Expectations After Hunter Syndrome Approval
Denali Therapeutics announced that the early commercial launch of AVLAYAH for pediatric Hunter syndrome is exceeding expectations, with initial patients already undergoing therapy and smooth reimbursement processes. The company anticipates a significant market opportunity for AVLAYAH due to its ability to treat both neurologic and whole-body diseases, unlike older therapies. Denali also highlighted its broader pipeline, including DNL126 for Sanfilippo syndrome and upcoming readouts for Parkinson's, tau, and frontotemporal dementia programs.
T. Rowe Price holds 5.4% of Denali Therapeutics (NASDAQ: DNLI)
T. Rowe Price Investment Management, Inc. has filed a Schedule 13G, disclosing a 5.4% beneficial ownership stake in Denali Therapeutics (NASDAQ: DNLI). This amounts to 8,519,192 shares as of March 31, 2026, with the filing indicating sole voting power over 8,503,878 shares and sole dispositive power over all 8,519,192 shares. The filing underscores T. Rowe Price's significant passive investment in the biotechnology company.
Morgan Stanley Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Cuts Target Price to $40
Morgan Stanley has reiterated its "Buy" rating for Denali Therapeutics (DNLI.US) but has lowered its target price to $40. This adjustment reflects an updated valuation while maintaining a positive outlook on the company's prospects.
Morgan Stanley Trims Price Target on Denali Therapeutics to $40 From $42, Keeps Overweight Rating
Morgan Stanley has adjusted its price target for Denali Therapeutics (NASDAQ: DNLI) to $40, down from the previous $42, while maintaining an Overweight rating on the stock. This revision reflects an updated valuation by the financial firm.
Denali Therapeutics stock (US24823R1077): Takeda exits DNL593 partnership
Denali Therapeutics has regained full rights to its investigational ALS and dementia drug DNL593 after Takeda's decision to exit their partnership. This allows Denali to independently advance the asset, with Phase 1/2 data expected by late 2026. The company focuses on neurodegenerative and lysosomal storage diseases, leveraging its Transport Vehicle technology.
Number of shareholders of Denali Therapeutics Inc. – SWB:4DN
The article provides information on the number of shareholders of Denali Therapeutics Inc., trading under the symbol 4DN on the Stuttgart Stock Exchange. It indicates that the market is currently closed with no trades. The period, value, and change in shareholder numbers are available in English.
DNLI Q1 loss narrower than expected, Avlayah approval boosts prospects
Denali Therapeutics (DNLI) reported a narrower-than-expected Q1 loss, despite missing revenue forecasts, largely due to milestone payments from its partnership with Sanofi contributing to a significant year-over-year revenue increase. The company's prospects were further bolstered by the FDA's recent approval of their co-developed multiple sclerosis drug, Tysabri (natalizumab) as Avlayah.
A Look At Denali Therapeutics (DNLI) Valuation After Accelerated FDA Approval Of AVLAYAH
Denali Therapeutics (DNLI) received accelerated FDA approval for AVLAYAH, its first commercial product, which has boosted its stock year-to-date. Despite this, the stock remains below its multi-year highs. The article examines Denali's valuation, noting its Price-to-Book ratio of 3.4x is above the broader US Biotechs industry average but below its peer group, reflecting investor sentiment on its pipeline potential and associated risks.
The Technical Signals Behind (DNLI) That Institutions Follow
This article analyzes Denali Therapeutics Inc. (NASDAQ: DNLI) using AI models to identify technical signals and institutional trading strategies. It highlights a positive near-term sentiment within a long-term strength context, noting an exceptional 46.8:1 risk-reward setup. The analysis provides specific entry and exit points for position, momentum breakout, and risk hedging strategies across different time horizons.
Denali Therapeutics stock (US24823R1077): FDA priority review for Hunter syndrome drug
Denali Therapeutics has received FDA priority review for its Biologics License Application for tividenofusp alfa, an investigational therapy for Hunter syndrome, with a PDUFA date of January 5, 2026. Despite a 3% stock drop on the initial announcement in July 2025, the company continues to advance its TransportVehicle platform, targeting neurodegenerative and lysosomal storage diseases. The therapy has received multiple designations, and analysts express optimism regarding its earnings potential.
Oppenheimer Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $40
Oppenheimer has reiterated its Buy rating for Denali Therapeutics (DNLI.US) and increased the target price to $40. This revision reflects the firm's continued confidence in Denali Therapeutics' stock.
Wedbush Adjusts Denali Therapeutics Price Target to $23 From $25, Maintains Outperform Rating
Wedbush has adjusted its price target for Denali Therapeutics (DNLI) to $23 from the previous $25, while retaining an "Outperform" rating on the stock. This revision comes ahead of the company's Q1 2026 earnings release, signaling a refined outlook from the firm, possibly influenced by recent company developments or market conditions.
Denali Therapeutics (NASDAQ: DNLI) adds cash on AVLAYAH deal despite Q1 loss
Denali Therapeutics reported a Q1 2026 net loss of $128.4 million, an improvement from the previous year, as operating expenses decreased. The company's cash reserves significantly increased to $1.05 billion, partly due to a $200 million payment from a synthetic royalty agreement with Royalty Pharma linked to AVLAYAH sales. AVLAYAH™ (tividenofusp alfa-eknm), approved in March 2026 for Hunter syndrome, began U.S. commercial distribution in April, marking Denali's first commercial revenue stream.
Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
Denali Therapeutics Inc. announced its financial results for the first quarter ended March 31, 2026, highlighting the FDA approval and U.S. launch of AVLAYAH (tividenofusp alfa-eknm) for Hunter syndrome. The company also provided updates on its broad clinical pipeline for lysosomal storage and neurodegenerative diseases, including progress on therapies for Alzheimer's and frontotemporal dementia. Denali reported a net loss of $128.4 million for the quarter and held approximately $1.05 billion in cash, cash equivalents, and marketable securities.
Press Release: Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
This press release details Denali Therapeutics' financial results and business highlights for the first quarter of 2026. It will cover key financial figures and important developments within the company during that period.
Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
Denali Therapeutics reported its Q1 2026 financial results and key business highlights, including the FDA approval and U.S. launch of AVLAYAH for neurologic Hunter syndrome, with the first commercial patients treated within a month. The company also announced progress in its clinical pipeline, such as dosing the first patient for DNL628 targeting tau for Alzheimer's and completing enrollment for DNL593 for frontotemporal dementia. Financially, Denali reported a net loss of $128.4 million but maintains strong cash reserves of approximately $1.05 billion.
Denali Therapeutics (DNLI) wins FDA nod for AVLAYAH and ends Q1 2026 with $1.05B cash
Denali Therapeutics reported significant milestones for Q1 2026, including FDA accelerated approval for AVLAYAH for Hunter syndrome, validating its TransportVehicle platform. The company ended the quarter with approximately $1.05 billion in cash and equivalent marketable securities, buoyed by a $200 million synthetic royalty funding agreement. Despite a net loss of $128.4 million, Denali is advancing a broad clinical pipeline and has initiated the U.S. commercial launch of AVLAYAH.
How many employees work at Denali Therapeutics?
According to Revelio Labs, Denali Therapeutics, Inc. has 545 employees as of December 2025, with a year-over-year growth rate of 16.1%. The article provides historical employee headcount data, showing an increase in 2025 after declines in previous years, and also mentions active job postings and other workforce metrics. Denali Therapeutics is focused on developing treatments for neurodegenerative diseases.
FMR LLC increases visibility on Denali (DNLI): 6.67M shares disclosed
FMR LLC has filed an amendment to a Schedule 13G/A, disclosing beneficial ownership of 6,672,999.32 shares of Denali Therapeutics (DNLI) common stock, which represents a 4.2% stake in the company. This filing indicates that FMR LLC holds sole dispositive power over these shares, clarifying their institutional exposure to Denali. The document details the beneficial ownership and percentage of the class, signed on May 5, 2026.
Denali Therapeutics (DNLI) Is Down 6.4% After Takeda Exits DNL593 Partnership - What's Changed
Denali Therapeutics (DNLI) shares dropped 6.4% after Takeda announced its termination of the DNL593 partnership, returning full development and commercialization rights to Denali. This gives Denali complete control over the drug and its underlying TransportVehicle technology, with phase I/II data expected by late 2026. While the exit removes a major partner and highlights execution risks and cash burn, it also offers Denali full upside potential for DNL593.
Assessing Denali Therapeutics (DNLI) Valuation After Takeda Ends DNL593 Partnership
Denali Therapeutics' valuation is being re-evaluated after Takeda ended its collaboration on the DNL593 frontotemporal dementia program, returning full rights to Denali. Despite recent share price declines, Denali's stock has seen a year-to-date gain, and analysts forecast significant revenue growth. The company's price-to-book ratio is 2.9x, which is lower than its peer group but higher than the broader US biotech industry, leading to mixed signals for investors considering its financial performance and pipeline progress.
Denali Therapeutics Inc. $DNLI Shares Bought by Pictet Asset Management Holding SA
Pictet Asset Management Holding SA significantly increased its stake in Denali Therapeutics Inc. ($DNLI) by 166.3% in Q4, now owning 1,329,108 shares valued at approximately $21.98 million. Denali Therapeutics reported better-than-expected Q4 EPS. The company has a "Moderate Buy" consensus rating from analysts with an average target price of $35.00, and institutional investors collectively own about 92.92% of the stock.
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Average Rating of "Moderate Buy" from Analysts
Denali Therapeutics Inc. (NASDAQ:DNLI) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $35.00. The company, a clinical-stage neurodegenerative biotech, is currently trading below analyst targets, and its shares opened at $18.60, down about 7.3%. Despite the recent dip, institutional investors have shown increased interest, boosting their holdings in the company.
10 Best Biotech Stocks with Highest Upside Potential
This article highlights Denali Therapeutics Inc. (NASDAQ: DNLI) as one of the top biotech stocks with high upside potential. It discusses the recent termination of its collaboration with Takeda for DNL593, a progranulin replacement therapy, clarifying that the decision was strategic and unrelated to the drug's efficacy or safety. Denali Therapeutics will regain full control over DNL593 and plans to present Phase I/II clinical trial findings by the end of 2026, emphasizing the potential of its TransportVehicle technology for neurodegenerative diseases.
B. Metzler seel. Sohn & Co. AG Makes New $1.84 Million Investment in Denali Therapeutics Inc. $DNLI
B. Metzler seel. Sohn & Co. AG has initiated a new position in Denali Therapeutics Inc. (NASDAQ:DNLI) by acquiring 112,300 shares valued at approximately $1.84 million during the fourth quarter. This investment highlights strong institutional interest, with major firms like Baillie Gifford, Vanguard, Holocene, and Aberdeen significantly increasing their stakes. Denali Therapeutics, a clinical-stage neurodegenerative therapeutics company, has a "Moderate Buy" consensus rating from analysts with an average price target of $35.00.
Denali Therapeutics dips after pricing $200M equity offering
Denali Therapeutics (DNLI) saw its shares dip following the pricing of a public offering of 11.1 million shares at $18 per share, aiming to raise $200 million. This offering includes a 30-day option for underwriters to purchase additional shares, and the company expects the offering to close on April 29.
Denali Therapeutics (NASDAQ:DNLI) Stock Rating Lowered by Wall Street Zen
Wall Street Zen downgraded Denali Therapeutics (NASDAQ:DNLI) from a "sell" to a "strong sell" rating. Despite this, the consensus among analysts remains a "Moderate Buy" with an average price target of $35. The stock currently trades around $19.87 with significant institutional ownership.
Leerink Partners Cuts Denali Therapeutics (NASDAQ:DNLI) Price Target to $35.00
Leerink Partners has lowered its price target for Denali Therapeutics (NASDAQ:DNLI) to $35.00 from $40.00 but maintained an "outperform" rating, suggesting a significant upside. Despite this cut, other firms like Morgan Stanley and Stifel have recently raised their price targets for DNLI, which currently holds a "Moderate Buy" consensus rating from analysts. The clinical-stage biopharmaceutical company focuses on neurodegenerative diseases with a high institutional ownership of 92.92%.
[ARS] Denali Therapeutics Inc. SEC Filing
This article announces an SEC filing by Denali Therapeutics Inc. (DNLI) of Form ARS, categorized as having low impact and neutral sentiment. The filing was accepted on April 21, 2026, and a PDF document is available. The article also provides recent news and other SEC filings related to Denali Therapeutics.
Denali Therapeutics (DNLI) Q4 2025 earnings summary
Denali Therapeutics (DNLI) reported its Q4 and FY 2025 earnings, highlighting a net loss of $128.5M for Q4 and $512.5M for the full year, with increased R&D and G&A expenses due to manufacturing expansion and launch preparations. The company is preparing for the commercial launch of tividenofusp alfa (DNL310) following an anticipated April 2026 FDA decision, and is advancing multiple other programs in lysosomal storage disorders and neurodegenerative diseases. Denali also secured $275M in synthetic royalty funding and completed a $200M public offering in December 2025, maintaining $966.2M in cash and equivalents.
Denali Therapeutics (DNLI) Stifel 2026 Virtual CNS Forum Summary
Denali Therapeutics presented a summary of its Stifel 2026 Virtual CNS Forum, highlighting 2026 as a crucial year with an anticipated first approval for tividenofusp alfa in Hunter syndrome, targeting both peripheral and neurological symptoms. The company also detailed pipeline progress, including new data on its Sanfilippo program and upcoming clinical trials in Alzheimer's and Pompe diseases, leveraging its transferrin receptor technology. Denali emphasized its differentiation in the competitive landscape through engineering innovations for improved drug delivery and tolerability, particularly in its Abeta brain shuttle and tau conjugate programs.
Denali CEO’s ‘greatest professional moment’ arrives as rare disease drug launches
Denali Therapeutics CEO Ryan Watts describes the FDA approval of Avlayah, a Hunter syndrome drug, as the "greatest professional moment" of his life, culminating 20 years of research into the blood-brain barrier. The approval on March 25, 2026, followed an intense journey, including a "clerical error" that caused a three-month delay, but validates Denali’s TransportVehicle technology for delivering medicines to the brain. Watts aims to leverage this success to develop treatments for other rare and common neurological diseases and build Denali into a standalone commercial biotech.
Denali Therapeutics (DNLI) CMO restates 204,402-share insider stake in Form 3/A
Denali Therapeutics Inc.'s Chief Medical Officer, Peter Scott Chin, has filed an amended Form 3/A to restate his direct ownership of 204,402 shares of the company's common stock. This filing clarifies his previously reported beneficial holdings and does not indicate any new purchases or sales of stock. The amendment specifically updates Table I to reflect these holdings.
Denali Therapeutics (NASDAQ: DNLI) sets 2026 virtual meeting and pay vote
Denali Therapeutics (NASDAQ: DNLI) has announced its 2026 virtual Annual Meeting of Stockholders for June 3, 2026, where shareholders will vote on the election of three Class III directors, the ratification of Ernst & Young LLP as the independent auditor, and an advisory vote on executive compensation. The board recommends voting "FOR" all proposals. The company also detailed its executive compensation philosophy, which links pay to performance, and provided updates on its clinical programs and financial activities throughout 2025.
Denali Therapeutics (DNLI) Proxy filing Summary
Denali Therapeutics has released a proxy filing summary detailing its upcoming annual meeting scheduled for June 3, 2026. Key items include the election of three directors, the ratification of Ernst & Young LLP as the accounting firm, and an advisory vote on executive compensation, all of which the board recommends approving. Shareholders can participate virtually and access proxy materials online or request copies by May 20, 2026.
Denali Therapeutics (DNLI) CMO details 170,612-share equity stake in Form 3
Denali Therapeutics' Chief Medical Officer, Peter Scott Chin, has filed an initial ownership report (Form 3) detailing his equity stake in the company. The report shows he holds 170,612 shares of common stock, including shares acquired through the Denali ESPP and 145,845 unvested Restricted Stock Units (RSUs). Additionally, Chin holds numerous vested and time-vesting stock options with exercise prices ranging from $20.17 to $80.03, expiring through 2036, which are typical equity-based compensation for a senior executive and do not signify new market transactions.
Technical Reactions to DNLI Trends in Macro Strategies
This article from Stock Traders Daily provides a technical analysis of Denali Therapeutics Inc. (NASDAQ: DNLI), highlighting a strong near-term sentiment with a long-term positive bias. It presents three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles, along with multi-timeframe signal analysis and risk-reward setups for the stock.
Orsini Selected as the Exclusive Specialty Pharmacy and Home Infusion Partner for Denali Therapeutics' AVLAYAH™ (tividenofusp alfa-eknm)
Orsini has been named the exclusive specialty pharmacy and home infusion partner for Denali Therapeutics' AVLAYAH™ (tividenofusp alfa-eknm), an FDA-approved enzyme replacement therapy for pediatric Hunter syndrome patients experiencing neurologic manifestations. This partnership enables Orsini to provide comprehensive home infusion support and adds AVLAYAH to its Neurology Center of Excellence, enhancing accessibility to this critical treatment. Orsini, a leader in rare disease pharmacy solutions, aims to ensure personalized, high-touch care for patients with this genetic metabolic condition.
Why Denali Therapeutics (DNLI) Is Up 7.4% After Regaining Full Rights To DNL593 Collaboration
Denali Therapeutics (DNLI) saw its stock rise by 7.4% after Takeda Pharmaceutical terminated their collaboration for DNL593, returning all program rights to Denali. This decision, driven by Takeda's internal priorities rather than safety or efficacy concerns, gives Denali full control over a promising Phase 1/2 asset. While regaining control concentrates development costs, it also highlights the importance of Denali's other programs and its blood-brain barrier platform in its investment narrative.
DNLI.O Stock News Today | Earnings, Events & Price Alerts
Denali Therapeutics (DNLI) has regained full control of its DNL593 therapy after Takeda terminated their collaboration agreement. Denali plans to continue the clinical development of DNL593, an investigational progranulin replacement therapy for frontotemporal dementia-granulin, and expects to report Phase 1/2 trial results by the end of 2026. The company also recently secured FDA accelerated approvals for its AVLAYAH product and highlighted the success of its TransportVehicle platform.
FDA clears Denali Therapeutics drug as first brain-penetrating biologic for rare disease
The FDA has approved Denali Therapeutics' drug for the treatment of a rare, inherited neurological disorder known as MPS IIIA or Sanfilippo syndrome. This marks the first time an enzyme replacement therapy has been cleared to enter the brain, offering a potential breakthrough for patients. The drug is designed to cross the blood-brain barrier to deliver the necessary enzyme.
Assessing Denali Therapeutics (DNLI) Valuation After Recent Share Pullback And Pipeline Growth Expectations
Denali Therapeutics (DNLI) has experienced a mixed share performance, with a recent pullback but overall gains over three months. The article assesses Denali's valuation, noting its price-to-book (P/B) multiple of 3x is higher than the US biotech average but significantly lower than its peer group, amid expectations of strong pipeline growth despite current net losses. It suggests that while the current price may reflect future growth potential, investors should also consider the inherent risks associated with early-stage biopharma companies.
How AVLAYAH’s Accelerated Approval and Takeda Exit Will Impact Denali Therapeutics (DNLI) Investors
Denali Therapeutics recently received accelerated FDA approval for AVLAYAH for Hunter syndrome and simultaneously learned that Takeda will end their co-development agreement for DNL593. These events highlight Denali's shift towards independently advancing its TransportVehicle-based pipeline. While AVLAYAH’s approval validates Denali's platform, the company faces growing reliance on self-funding its capital-intensive pipeline, prompting investors to weigh platform potential against execution, regulatory, and financing risks.
Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (DNLI) and Fennec Pharmaceuticals (FENC)
Healthcare sector analysts have issued bullish sentiments for Denali Therapeutics (DNLI) and Fennec Pharmaceuticals (FENC). H.C. Wainwright maintained a Buy rating for Denali with a $42 price target, while Craig-Hallum maintained a Buy rating for Fennec, which has a consensus price target of $15. Both companies show strong buy consensus from analysts, indicating significant upside potential.
